289 related articles for article (PubMed ID: 21030558)
21. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Bello C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM
Br J Haematol; 2007 Nov; 139(3):415-24. PubMed ID: 17910631
[TBL] [Abstract][Full Text] [Related]
22. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial.
Mai EK; Benner A; Bertsch U; Brossart P; Hänel A; Kunzmann V; Naumann R; Neben K; Egerer G; Ho AD; Hillengass J; Raab MS; Neubauer A; Peyn A; Ko YD; Peter N; Scheid C; Goldschmidt H
Br J Haematol; 2016 Jun; 173(5):731-41. PubMed ID: 26990892
[TBL] [Abstract][Full Text] [Related]
23. T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy.
Chung DJ; Pronschinske KB; Shyer JA; Sharma S; Leung S; Curran SA; Lesokhin AM; Devlin SM; Giralt SA; Young JW
Cancer Immunol Res; 2016 Jan; 4(1):61-71. PubMed ID: 26464015
[TBL] [Abstract][Full Text] [Related]
24. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.
Morisaki T; Matsumoto K; Onishi H; Kuroki H; Baba E; Tasaki A; Kubo M; Nakamura M; Inaba S; Yamaguchi K; Tanaka M; Katano M
Hum Cell; 2003 Dec; 16(4):175-82. PubMed ID: 15147037
[TBL] [Abstract][Full Text] [Related]
25. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
Massaia M; Borrione P; Battaglio S; Mariani S; Beggiato E; Napoli P; Voena C; Bianchi A; Coscia M; Besostri B; Peola S; Stiefel T; Even J; Novero D; Boccadoro M; Pileri A
Blood; 1999 Jul; 94(2):673-83. PubMed ID: 10397734
[TBL] [Abstract][Full Text] [Related]
26. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
Wang X; Popplewell LL; Wagner JR; Naranjo A; Blanchard MS; Mott MR; Norris AP; Wong CW; Urak RZ; Chang WC; Khaled SK; Siddiqi T; Budde LE; Xu J; Chang B; Gidwaney N; Thomas SH; Cooper LJ; Riddell SR; Brown CE; Jensen MC; Forman SJ
Blood; 2016 Jun; 127(24):2980-90. PubMed ID: 27118452
[TBL] [Abstract][Full Text] [Related]
27.
Khalaf WS; Garg M; Mohamed YS; Stover CM; Browning MJ
Front Immunol; 2019; 10():1792. PubMed ID: 31428094
[TBL] [Abstract][Full Text] [Related]
28. [The preparation of myeloma-specific T cells activated with dendritic cells loaded with nonapeptides derived from mucin protein MUC1 and catalytic subunit of telomerase hTERT].
Ocadlíková D; Kovárová L; Hájek R; Michálek J
Klin Onkol; 2008; 21(2):59-65. PubMed ID: 19102213
[TBL] [Abstract][Full Text] [Related]
29. Cellular immunotherapy for plasma cell myeloma.
Garfall AL; Vogl DT; Weiss BM; Stadtmauer EA
Bone Marrow Transplant; 2013 Nov; 48(11):1377-86. PubMed ID: 23645169
[TBL] [Abstract][Full Text] [Related]
30. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma.
Noonan KA; Huff CA; Davis J; Lemas MV; Fiorino S; Bitzan J; Ferguson A; Emerling A; Luznik L; Matsui W; Powell J; Fuchs E; Rosner GL; Epstein C; Rudraraju L; Ambinder RF; Jones RJ; Pardoll D; Borrello I
Sci Transl Med; 2015 May; 7(288):288ra78. PubMed ID: 25995224
[TBL] [Abstract][Full Text] [Related]
31. Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma.
Yousef S; Heise J; Lajmi N; Bartels K; Kröger N; Luetkens T; Atanackovic D
J Transl Med; 2015 Jun; 13():197. PubMed ID: 26088750
[TBL] [Abstract][Full Text] [Related]
32. Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
Brunsvig PF; Guren TK; Nyakas M; Steinfeldt-Reisse CH; Rasch W; Kyte JA; Juul HV; Aamdal S; Gaudernack G; Inderberg EM
Front Immunol; 2020; 11():572172. PubMed ID: 33324397
[TBL] [Abstract][Full Text] [Related]
33. Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma.
González-Calle V; Cerdá S; Labrador J; Sobejano E; González-Mena B; Aguilera C; Ocio EM; Vidriales MB; Puig N; Gutiérrez NC; García-Sanz R; Alonso JM; López R; Aguilar C; de Coca AG; Hernández R; Hernández JM; Escalante F; Mateos MV
Haematologica; 2017 May; 102(5):922-931. PubMed ID: 28126960
[TBL] [Abstract][Full Text] [Related]
34. Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant.
Chung DJ; Sharma S; Rangesa M; DeWolf S; Elhanati Y; Perica K; Young JW
Blood Adv; 2022 Mar; 6(5):1547-1558. PubMed ID: 35100339
[TBL] [Abstract][Full Text] [Related]
35. In vitro activation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells.
Kryukov F; Ocadlíková D; Kovárová L; Buresová I; Hájek R; Michálek J
J Immunotoxicol; 2009 Dec; 6(4):243-8. PubMed ID: 19908943
[TBL] [Abstract][Full Text] [Related]
36. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
Zeis M; Frenzke H; Schmitz N; Uharek L; Steinmann J
Bone Marrow Transplant; 2002 Feb; 29(3):213-21. PubMed ID: 11859393
[TBL] [Abstract][Full Text] [Related]
37. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.
Mehrotra S; Britten CD; Chin S; Garrett-Mayer E; Cloud CA; Li M; Scurti G; Salem ML; Nelson MH; Thomas MB; Paulos CM; Salazar AM; Nishimura MI; Rubinstein MP; Li Z; Cole DJ
J Hematol Oncol; 2017 Apr; 10(1):82. PubMed ID: 28388966
[TBL] [Abstract][Full Text] [Related]
38. Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine.
Jing W; Orentas RJ; Johnson BD
Biol Blood Marrow Transplant; 2007 Mar; 13(3):277-92. PubMed ID: 17317581
[TBL] [Abstract][Full Text] [Related]
39. Adoptive cellular therapy using cells enriched for NKG2D+CD3+CD8+T cells after autologous transplantation for myeloma.
Meehan KR; Talebian L; Tosteson TD; Hill JM; Szczepiorkowski Z; Sentman CL; Ernstoff MS
Biol Blood Marrow Transplant; 2013 Jan; 19(1):129-37. PubMed ID: 22975165
[TBL] [Abstract][Full Text] [Related]
40. Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect.
Circosta P; Vitaggio K; Elia AR; Todorovic M; Sangiolo D; Carnevale-Schianca F; Vallario A; Geuna M; Aglietta M; Cignetti A
Immunotherapy; 2018 Jul; 10(9):753-767. PubMed ID: 30008257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
